Please login to the form below
Apellis Pharmaceuticals
This page shows the latest Apellis Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Latest appointments
-
Dr Robert Kim joins Apellis as chief medical officer
Brings experience from Novartis, Genentech and GSK. Dr Robert Kim has taken up a role at Apellis Pharmaceuticals as chief medical officer, bringing to the US clinical stage immunotherapy company experience ... In his new role at Louisville,
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
